Tiefe Hirnstimulation bei der Schizophrenie

J. Kuhn; M. Bodatsch; V. Sturm; D. Lenartz; J. Klosterkötter; P. J. Uhlhaas; C. Winter; T. O. J. Gründler

doi:10.1055/s-0031-1281733

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2011; 79(11): 632-641
DOI: 10.1055/s-0031-1281733

Übersicht

Tiefe Hirnstimulation bei der Schizophrenie

Deep Brain Stimulation in SchizophreniaJ. Kuhn¹ [*] ¹ , M. Bodatsch¹ [*] ¹ , V. Sturm² , D. Lenartz² , J. Klosterkötter¹ , P. J. Uhlhaas³ , C. Winter⁴ , T. O. J. Gründler⁵

¹Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum der Universität Köln
²Klinik für Stereotaxie und funktionelle Neurochirurgie, Klinikum der Universität Köln
³Max-Planck-Institut für Hirnforschung, Frankfurt a. M.
⁴Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus
⁵Max-Planck-Institut für neurologische Forschung, Köln

Abstract

Zusammenfassung

Die tiefe Hirnstimulation (THS) hat die Grenzen der Behandlungsmöglichkeiten einiger, vermeintlich therapieresistenter, neuropsychiatrischer Erkrankungen erfolgreich erweitert. Vor diesem Hintergrund werden immer mehr psychische Störungen im Stadium der Therapieresistenz als mögliche Indikationen der THS erwogen. Mittlerweile ist auch die Schizophrenie in den Fokus des Interesses gelangt. Diese, wie alle anderen potenziellen psychiatrischen Indikationen, bedürfen der kritischen Prüfung, ob der aktuelle Wissensstand in Hinblick auf die propagierten Wirkmechanismen der THS und die angenommene Pathophysiologie der Erkrankung einen Einsatz des Verfahrens rechtfertigen. Die vorliegende Arbeit betrachtet synoptisch die aktuellen Ansätze, die einen THS-Einsatz begründen könnten, und diskutiert die Übertragbarkeit bisheriger THS-Anwendungen, Studienergebnisse zur dopaminergen Transmission und zu neuronalen Oszillationen sowie tierexperimentelle Daten. In der Zusammenschau ist die aktuelle Datenlage durchaus zukunftsweisend für einige Symptome der Schizophrenie, rechtfertigt zum gegenwärtigen Zeitpunkt jedoch womöglich noch nicht den klinischen Einsatz der THS in der Behandlung. Vordringliche Aufgabe ist der Schluss bis dato bestehender Wissenslücken, um indikationsbegründende Hypothesen mit möglichst geringem Spekulationscharakter generieren zu können.

Abstract

Deep brain stimulation (DBS) has successfully advanced our treatment options for putative therapy-resistant neuropsychiatric diseases. Building on this strong foundation, more and more mental disorders in the stadium of therapy-resistance are considered as possible indications for DBS. Especially, schizophrenia with its associated severe and difficult to treat symptoms is gaining attention. This attention demands critical questions regarding the assumed mechanisms of DBS and its possible influence on the supposed pathophysiology of schizophrenia. Here, we synoptically compare current approaches and theories of DBS and discuss the feasibility of DBS in schizophrenia as well as the transferability from other psychiatric disorders successfully treated with DBS. For this we consider recent advances in animal models of schizophrenic symptoms, results regarding the influence of DBS on dopaminergic transmission as well as data concerning neural oscillation and synchronisation. In conclusion, the use of DBS for some symptoms of schizophrenia seems to be a promising approach, but the lack of a comprehensive theory of the mechanisms of DBS as well as its impact on schizophrenia might hinder the use of DBS for schizophrenia at this point in time.

Schlüsselwörter

Tiefe Hirnstimulation - Schizophrenie - Translationale Medizin - Neuronale Oszillationen

Keywords

deep brain stimulation - schizophrenia - translational medicine - neural oscillations

Full Text

References

Literatur

1 Benabid A L, Pollak P, Louveau A et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol. 1987; 50 (1 – 6) 344-346
2 Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006; 355 (9) 896-908
3 Kupsch A, Benecke R, Muller J et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006; 355 (19) 1978-1990
4 Schuurman P R, Bosch D A, Bossuyt P M et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med. 2000; 342 (7) 461-468
5 Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. The New England journal of medicine. 2006; 355 (9) 896-908
6 Skuban T, Flohrer, Klosterkoetter J et al. Psychiatrische Nebenwirkungen der tiefen Hirnstimulation bei M. Parkinson. submitted
7 Nuttin B, Cosyns P, Demeulemeester H et al. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet. 1999; 354 (9189) 1526
8 Vandewalle V, Linden van der C, Groenewegen H J et al. Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet. 1999; 353 (9154) 724
9 Kuhn J, Gründler T OJ, Lenartz D et al. Deep brain stimulation for psychiatric disorders. Dtsch Arztebl Int. 2010; 107 (7) 105-113
10 Kuhn J, Gründler T OJ, Bauer R et al. Observations on cognitive control during successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence. submitted
11 Kuhn J, Lenartz D, Huff W et al. Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications?. J Neurol Neurosurg Psychiatry. 2007; 78 (10) 1152-1153
12 Laxton A W, Tang-Wai D F, McAndrews M P et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol. 2010; 68 (4) 521-534
13 Huys D, Möller M, Kim E et al. Die historischen Grundlagen der tiefen Hirnstimulation bei psychiatrischen Erkrankungen. Nervenarzt. 2011 Aug 25 [Epub ahead of print]
14 Trottenberg T, Volkmann J, Deuschl G et al. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology. 2005; 64 (2) 344-346
15 Damier P, Thobois S, Witjas T et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Archives of general psychiatry. 2007; 64 (2) 170-176
16 Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane database of systematic reviews. 2009; 3 CD006324
17 Kirkpatrick B, Fenton W S, Carpenter W T et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia bulletin. 2006; 32 (2) 214-219
18 Os van J, Kapur Jr S. Schizophrenia. Lancet. 2009; 374 (9690) 635-645
19 Wittchen H U, Essau C A, Zerssen von D et al. Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study. European archives of psychiatry and clinical neuroscience. 1992; 241 (4) 247-258
20 Perala J, Suvisaari J, Saarni S I et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of general psychiatry. 2007; 64 (1) 19-28
21 Skantze K. Subjective quality of life and standard of living: a 10-year follow-up of out-patients with schizophrenia. Acta psychiatrica Scandinavica. 1998; 98 (5) 390-399
22 Pinikahana J, Happell B, Hope J et al. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. International journal of mental health nursing. 2002; 11 (2) 103-111
23 Castle D J, Morgan V. Epidemiology. In: Mueser K T, Jeste D V, eds Clinical handbook of schizophrenia. New York: The Guilford Press; 2008: 14-24
24 Andreasen N C, Carpenter Jr W T, Kane J M et al. Remission in schizophrenia: proposed criteria and rationale for consensus. The American journal of psychiatry. 2005; 162 (3) 441-449
25 Lambert M, Karow A, Leucht S et al. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues in clinical neuroscience. 2010; 12 (3) 393-407
26 Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England journal of medicine. 2003; 349 (20) 1925-1934
27 Oh M Y, Abosch A, Kim S H et al. Long-term hardware-related complications of deep brain stimulation. Neurosurgery. 2002; 50 (6) 1268-1274 ; discussion 1274 – 1276
28 Müller S, Christen M. Deep Brain Stimulation in Parkinsonian Patients – Ethical Evaluation of Cognitive, Affective, and Behavioral Sequelae. AJOB Neuroscience. 2011; 2 (1) 3-13
29 McIntyre C C, Savasta M, Kerkerian-Le Goff L et al. Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. Clin Neurophysiol. 2004; 115 (6) 1239-1248
30 Dostrovsky J O, Levy R, Wu J P et al. Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J Neurophysiol. 2000; 84 (1) 570-574
31 Beurrier C, Bioulac B, Audin J et al. High-frequency stimulation produces a transient blockade of voltage-gated currents in subthalamic neurons. J Neurophysiol. 2001; 85 (4) 1351-1356
32 Leiphart J W, Valone3 rd F H. Stereotactic lesions for the treatment of psychiatric disorders. J Neurosurg. 2010; 113 (6) 1204-1211
33 Ridding M C, Rothwell J C. Is there a future for therapeutic use of transcranial magnetic stimulation?. Nat Rev Neurosci. 2007; 8 (7) 559-567
34 Pascual-Leone A, Bartres-Faz D, Keenan J P. Transcranial magnetic stimulation: studying the brain-behaviour relationship by induction of ‘virtual lesions’. Philos Trans R Soc Lond B Biol Sci. 1999; 354 (1387) 1229-1238
35 Jandl M. The use of repetitive transcranial magnetic stimulation (rTMS) in auditory verbal hallucinations (AVH). Fortschr Neurol Psychiatr. 2010; 78 (11) 632-643
36 Aleman A, Sommer I E, Kahn R S. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. The Journal of clinical psychiatry. 2007; 68 (3) 416-421
37 Slotema C W, Blom J D, Hoek H W et al. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. The Journal of clinical psychiatry. 2010; 71 (7) 873-884
38 Slotema C W, Blom J D, Weijer A D et al. Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological psychiatry. 2011; 69 (5) 450-456
39 Payne N A, Prudic de J. Electroconvulsive therapy: Part I. A perspective on the evolution and current practice of ECT. Journal of psychiatric practice. 2009; 15 (5) 346-368
40 Kato N. Neurophysiological mechanisms of electroconvulsive therapy for depression. Neuroscience research. 2009; 64 (1) 3-11
41 Daniels J. Catatonia: clinical aspects and neurobiological correlates. The Journal of neuropsychiatry and clinical neurosciences. 2009; 21 (4) 371-380
42 Sanacora G, Mason G F, Rothman D L et al. Increased cortical GABA concentrations in depressed patients receiving ECT. The American journal of psychiatry. 2003; 160 (3) 577-579
43 Northoff G. What catatonia can tell us about „top-down modulation“: a neuropsychiatric hypothesis. The Behavioral and brain sciences. 2002; 25 (5) 555-577 ; discussion 578 – 604
44 Mikell C B, McKhann G M, Segal S et al. The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact Funct Neurosurg. 2009; 87 (4) 256-265
45 Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003; 160 (1) 13-23
46 Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis – linking biology, pharmacology and phenomenology of psychosis. Schizophrenia research. 2005; 79 (1) 59-68
47 Goto Y, Otani S, Grace A A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology. 2007; 53 (5) 583-587
48 Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27 (7) 1081-1090
49 Juckel G, Schlagenhauf F, Koslowski M et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology. 2006; 187 (2) 222-228
50 Rosenfeld A J, Lieberman J A, Jarskog L F. Oxytocin, Dopamine, and the Amygdala: A Neurofunctional Model of Social Cognitive Deficits in Schizophrenia. Schizophr Bull. 2011; 37 (5) 1077-1087
51 Harvey P D, Koren D, Reichenberg A et al. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr Bull. 2006; 32 (2) 250-258
52 Ventura J, Hellemann G S, Thames A D et al. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009; 113 (2 – 3) 189-199
53 Juckel G, Schlagenhauf F, Koslowski M et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006; 29 (2) 409-416
54 Niv Y, Daw N D, Joel D et al. Tonic dopamine: opportunity costs and the control of response vigor. Psychopharmacology. 2007; 191 (3) 507-520
55 Schlaepfer T E, Cohen M X, Frick C et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008; 33 (2) 368-377
56 Hamamura T, Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology. 2007; 191 (3) 741-743
57 Mazza M, Squillacioti M R, Pecora R D et al. Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. Psychiatry Res. 2009; 165 (1 – 2) 193-196
58 Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373 (9657) 31-41
59 Sandyk R. Pineal and habenula calcification in schizophrenia. Int J Neurosci. 1992; 67 (1 – 4) 19-30
60 Corfas G, Roy K, Buxbaum J D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci. 2004; 7 (6) 575-580
61 Williams N M, Preece A, Spurlock G et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry. 2003; 8 (5) 485-487
62 Yang J Z, Si T M, Ruan Y et al. Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry. 2003; 8 (7) 706-9
63 Steiner H, Blum M, Kitai S T et al. Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat. Exp Neurol. 1999; 159 (2) 494-503
64 Lecourtier L, Kelly P H. Bilateral lesions of the habenula induce attentional disturbances in rats. Neuropsychopharmacology. 2005; 30 (3) 484-496
65 Lecourtier L, Neijt H C, Kelly P H. Habenula lesions cause impaired cognitive performance in rats: implications for schizophrenia. Eur J Neurosci. 2004; 19 (9) 2551-2560
66 Heldt S A, Ressler K J. Lesions of the habenula produce stress- and dopamine-dependent alterations in prepulse inhibition and locomotion. Brain Res. 2006; 1073 – 1074 229-239
67 Shepard P D, Holcomb H H, Gold J M. Schizophrenia in translation: the presence of absence: habenular regulation of dopamine neurons and the encoding of negative outcomes. Schizophr Bull. 2006; 32 (3) 417-421
68 Paul G, Reum T, Meissner W et al. High frequency stimulation of the subthalamic nucleus influences striatal dopaminergic metabolism in the naive rat. Neuroreport. 2000; 11 (3) 441-444
69 Meissner W, Harnack D, Reese R et al. High-frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. J Neurochem. 2003; 85 (3) 601-609
70 Meissner W, Harnack D, Paul G et al. Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. Neurosci Lett. 2002; 328 (2) 105-108
71 Meissner W, Reum T, Paul G et al. Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. Neurosci Lett. 2001; 303 (3) 165-168
72 Winter C, Lemke C, Sohr R et al. High frequency stimulation of the subthalamic nucleus modulates neurotransmission in limbic brain regions of the rat. Exp Brain Res. 2008; 185 (3) 497-507
73 Benazzouz A, Piallat B, Pollak P et al. Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci Lett. 1995; 189 (2) 77-80
74 Benazzouz A, Gao D M, Ni Z G et al. Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. Neuroscience. 2000; 99 (2) 289-295
75 Benazzouz A, Gao D, Ni Z et al. High frequency stimulation of the STN influences the activity of dopamine neurons in the rat. Neuroreport. 2000; 11 (7) 1593-1596
76 Robledo P, Feger J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res. 1990; 518 (1 – 2) 47-54
77 Bruet N, Windels F, Carcenac C et al. Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats. J Neuropathol Exp Neurol. 2003; 62 (12) 1228-1240
78 Buzsaki G, Draguhn A. Neuronal oscillations in cortical networks. Science. 2004; 304 (5679) 1926-1929
79 Uhlhaas P J, Roux F, Singer W et al. The development of neural synchrony reflects late maturation and restructuring of functional networks in humans. Proc Natl Acad Sci U S A. 2009; 106 (24) 9866-9871
80 Stein von A, Sarnthein J. Different frequencies for different scales of cortical integration: from local gamma to long range alpha/theta synchronization. Int J Psychophysiol. 2000; 38 (3) 301-313
81 Uhlhaas P J, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010; 11 (2) 100-113
82 Boutros N. Lack of blinding in gating studies. Schizophr Res. 2008; 103 (1 – 3) 336 ; author reply 337
83 Spencer K M, Nestor P G, Perlmutter R et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A. 2004; 101 (49) 17 288-17 293
84 Uhlhaas P J, Haenschel C, Nikolic D et al. The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull. 2008; 34 (5) 927-943
85 Uhlhaas P J, Linden D E, Singer W et al. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci. 2006; 26 (31) 8168-8175
86 Haenschel C, Linden D E, Bittner R A et al. Alpha phase locking predicts residual working memory performance in schizophrenia. Biol Psychiatry. 2010; 68 (7) 595-598
87 Rolls E T, Loh M, Deco G et al. Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nat Rev Neurosci. 2008; 9 (9) 696-709
88 Teubner M D, Nixon J B, Rasser P E et al. Source localisation in a real human head. Brain Topogr. 2005; 17 (4) 197-205
89 Timmermann L, Gross J, Butz M et al. Pathological oscillatory coupling within the human motor system in different tremor syndromes as revealed by magnetoencephalography. Neurol Clin Neurophysiol. 2004; 26
90 Timmermann L, Gross J, Dirks M et al. The cerebral oscillatory network of parkinsonian resting tremor. Brain. 2003; 126 (Pt 1) 199-212
91 Kuhn A A, Kupsch A, Schneider G H et al. Reduction in subthalamic 8 – 35 Hz oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur J Neurosci. 2006; 23 (7) 1956-1960
92 Kuhn A A, Williams D, Kupsch A et al. Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain. 2004; 127 (Pt 4) 735-746
93 Meissner W, Leblois A, Hansel D et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain. 2005; 128 (Pt 10) 2372-2382
94 Gallinat J, Mulert C, Bajbouj M et al. Frontal and temporal dysfunction of auditory stimulus processing in schizophrenia. Neuroimage. 2002; 17 (1) 110-127
95 Javitt D C. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu Rev Clin Psychol. 2009; 5 249-275
96 Adcock R A, Dale C, Fisher M et al. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr Bull. 2009; 35 (6) 1132-1141
97 Arends M, Winterer G. Tiefe Hirnstimulation bei Schizophrenie – Ein neues Forschungsprojekt. Nervenarzt. 2008; Suppl 4 470
98 Gross A, Joutsiniemi S L, Rimon R et al. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry. 2004; 37 (3) 119-122
99 Andreasen N C. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa Press; 1983
100 Gschwandtner U, Zimmermann R, Pflueger M O et al. Negative symptoms in neuroleptic-naive patients with first-episode psychosis correlate with QEEG parameters. Schizophr Res. 2009; 115 (2 – 3) 231-236
101 Singer W. Neuronal synchrony: a versatile code for the definition of relations?. Neuron. 1999; 24 (1) 49-65, 111 – 125
102 Mundt A, Klein J, Joel D et al. High-frequency stimulation of the nucleus accumbens core and shell reduces quinpirole-induced compulsive checking in rats. Eur J Neurosci. 2009; 29 (12) 2401-2412
103 Klavir O, Flash S, Winter C et al. High frequency stimulation and pharmacological inactivation of the subthalamic nucleus reduces ‘compulsive’ lever-pressing in rats. Exp Neurol. 2009; 215 (1) 101-109
104 Klavir O, Winter C, Joel D. High but not low frequency stimulation of both the globus pallidus and the entopeduncular nucleus reduces ‘compulsive’ lever-pressing in rats. Behav Brain Res. 2011; 216 (1) 84-93
105 Djodari-Irani A, Klein J, Banzhaf J et al. HFS and pharmacological inactivation of the globus pallidus and nucleus entopeduncularis differentially affect quinpirole-induced compulsive checking in rats. European Neuropsychopharmacology. 2010; 20 S281-S282
106 Winter C, Flash S, Klavir O et al. The role of the subthalamic nucleus in ‘compulsive’ behavior in rats. Eur J Neurosci. 2008; 27 (8) 1902-1911
107 Hamani C, Nobrega J N. Deep brain stimulation in clinical trials and animal models of depression. Eur J Neurosci. 2010; 32 (7) 1109-1117
108 Hamani C, Diwan M, Macedo C E et al. Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry. 2010; 67 (2) 117-124
109 Vassoler F M, Schmidt H D, Gerard M E et al. Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. J Neurosci. 2008; 28 (35) 8735-8739
110 Rouaud T, Lardeux S, Panayotis N et al. Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proc Natl Acad Sci U S A. 2010; 107 (3) 1196-1200
111 Winter C, Harnack D, Kupsch A. Deep brain stimulation for neurological and psychiatric diseases: animal experiments on effect and mechanisms. Nervenarzt. 2010; 81 (6) 711-718
112 Feldon J, Weiner I. Editorial: Special issue on modeling schizophrenia. Behav Brain Res. 2009; 204 (2) 255-257
113 Andreasen N C. The American concept of schizophrenia. Schizophr Bull. 1989; 15 (4) 519-531
114 Klosterkotter J. The revised definitions of schizophrenic disorders in ICD-10 and DSM-IV. Fortschr Neurol Psychiatr. 1998; 66 (3) 133-143
115 Kirkpatrick B, Fenton W S, Carpenter Jr W T et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006; 32 (2) 214-219
116 Carter C S, Barch D M, Buchanan R W et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry. 2008; 64 (1) 4-10
117 Nuechterlein K H, Green M F, Kern R S et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165 (2) 203-213

1 Die Autoren J. Kuhn und M. Bodatsch haben in gleicher Weise zum Manuskript beigetragen.

Prof. Jens Kuhn

Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum der Universität Köln

Kerpener Str. 62

50937 Köln

Email: jens.kuhn@uk-koeln.de